We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Buy Haemonetics (HAE) Stock Right Now
Read MoreHide Full Article
Haemonetics Corporation (HAE - Free Report) has been gaining investor confidence on continued positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 74.7% against the industry’s 1.8% fall. Also, the company has outperformed the S&P 500’s 2.7% decline.
This renowned global provider of blood management solutions to customers encompassing blood and plasma collectors and hospitals has a market cap of $5.32 billion. The company has an earnings growth rate of 12.5% for the next three to five years.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What Makes the Stock an Attractive Pick?
Potential Upside of Plasma Franchise
Haemonetics has been witnessing strong growth in Plasma franchise for quite some time. Plasma continued to witness strong growth in the fiscal second quarter on a 13.3% rise in revenues at constant currency. In the quarter, North America Plasma revenues increased 17% led by strength in disposables along with growing software revenues.
Haemonetics expects to maintain growth in the commercial Plasma collection business and has raised the fiscal 2019 guidance for revenue growth to 14-16% (7-10% stated earlier).
Huge Potential of Hemostasis Management Franchise
Under Hospital business, Hemostasis Management saw strong growth in the past few quarters. Also, TEG has become the global leader in Hemostasis Management led by solid disposable growth and higher TEG success capital sales.
During the first quarter, Haemonetics launched a product line extension, namely, TEG Manager 4.0, a software solution with a new feature called the interpretation guidance module.
The TEG 6s product offering contributed significantly to Hemostasis’ revenues in fiscal 2018. The company witnessed double-digit sales growth in both TEG 5000 and TEG 6s disposables and above 20% growth in major TEG markets of North America, China and Europe, Middle East and Africa in the fiscal second quarter.
Strong Balance Sheet
Haemonetics exited the second quarter of fiscal 2019 with cash and cash equivalents of $199.8 million compared with $192.1 million at the end of the first quarter of fiscal 2019.
The company generated operating cash flow of $80.5 million in the first six months of the fiscal compared with $97.3 million a year ago. The company also reported free cash flow (before restructuring and turnaround costs) of $20.8 million during the same period compared with $75.3 million a year ago. Capital expenditures totaled $75.3 million in this period, higher than $27.8 million a year ago.
Other Key Picks
Other top-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Surmodics, Inc. (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Integer Holdings, with a Zacks Rank #2, has an earnings growth rate of 31.2% for the first quarter of 2019.
Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 currently.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Here's Why You Should Buy Haemonetics (HAE) Stock Right Now
Haemonetics Corporation (HAE - Free Report) has been gaining investor confidence on continued positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 74.7% against the industry’s 1.8% fall. Also, the company has outperformed the S&P 500’s 2.7% decline.
This renowned global provider of blood management solutions to customers encompassing blood and plasma collectors and hospitals has a market cap of $5.32 billion. The company has an earnings growth rate of 12.5% for the next three to five years.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What Makes the Stock an Attractive Pick?
Potential Upside of Plasma Franchise
Haemonetics has been witnessing strong growth in Plasma franchise for quite some time. Plasma continued to witness strong growth in the fiscal second quarter on a 13.3% rise in revenues at constant currency. In the quarter, North America Plasma revenues increased 17% led by strength in disposables along with growing software revenues.
Haemonetics expects to maintain growth in the commercial Plasma collection business and has raised the fiscal 2019 guidance for revenue growth to 14-16% (7-10% stated earlier).
Huge Potential of Hemostasis Management Franchise
Under Hospital business, Hemostasis Management saw strong growth in the past few quarters. Also, TEG has become the global leader in Hemostasis Management led by solid disposable growth and higher TEG success capital sales.
During the first quarter, Haemonetics launched a product line extension, namely, TEG Manager 4.0, a software solution with a new feature called the interpretation guidance module.
The TEG 6s product offering contributed significantly to Hemostasis’ revenues in fiscal 2018. The company witnessed double-digit sales growth in both TEG 5000 and TEG 6s disposables and above 20% growth in major TEG markets of North America, China and Europe, Middle East and Africa in the fiscal second quarter.
Strong Balance Sheet
Haemonetics exited the second quarter of fiscal 2019 with cash and cash equivalents of $199.8 million compared with $192.1 million at the end of the first quarter of fiscal 2019.
The company generated operating cash flow of $80.5 million in the first six months of the fiscal compared with $97.3 million a year ago. The company also reported free cash flow (before restructuring and turnaround costs) of $20.8 million during the same period compared with $75.3 million a year ago. Capital expenditures totaled $75.3 million in this period, higher than $27.8 million a year ago.
Other Key Picks
Other top-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Surmodics, Inc. (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock carries a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Integer Holdings, with a Zacks Rank #2, has an earnings growth rate of 31.2% for the first quarter of 2019.
Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 currently.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>